X

Drug Profile

HMB 001

Alternative Names: HMB-001

Latest Information Update: 15 Feb 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Hemab
Class Antihaemorrhagics; Bispecific antibodies; Recombinant proteins
Mechanism of Action Factor VIIa modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Thrombasthenia
Preclinical Factor VII deficiency

Most Recent Events

09 Feb 2024 Adverse events, pharmacodynamics and pharmacokinetics data from phase I/II trial in Thrombasthenia were released by company
11 Dec 2023 Hemab Therapeutics receives IND approval form US FDA in Thrombasthenia
11 Dec 2023 HMB 001 receives Fast Track designation for Thrombasthenia [Parenteral] in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com